Low Wilms’ Tumor Gene Expression in Tumor Tissues Predicts Poor Prognosis in Patients with Non-Small-Cell Lung Cancer

REFERENCES

• Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C, Housman DE. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 1990;60:509–520.
   PubMed Web of Science ®Google Scholar
• Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990;343:774–778.
   PubMed Web of Science ®Google Scholar
• Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A 1991;88:9618–9622.
   PubMed Web of Science ®Google Scholar
• Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ, 3rd, Kim SJ. Repression of the transforming growth factor-beta 1 gene by the Wilms’ tumor suppressor WT1 gene product. Mol Endocrinol 1994;8:595–602.
   PubMed Web of Science ®Google Scholar
• Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ, 3rd. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992;257:674–678.
   PubMed Web of Science ®Google Scholar
• Gashler AL, Bonthron DT, Madden SL, Rauscher FJ, 3rd, Collins T, Sukhatme VP. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci U S A 1992;89:10984–10988.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Madden SL, Deuel TF, Rauscher FJ, 3rd. The Wilms’ tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 1992;267:21999–22002.
   PubMed Web of Science ®Google Scholar
• Werner H, Re GG, Drummond IA, Sukhatme VP, Rauscher FJ, 3rd, Sens DA, Garvin AJ, LeRoith D, Roberts CT, Jr. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci U S A 1993;90:5828–5832.
   PubMed Web of Science ®Google Scholar
• Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ, 3rd, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms’ tumor suppressor gene WT1. Cancer Res 1995;55:5386–5389.
   PubMed Web of Science ®Google Scholar
• Luo XN, Reddy JC, Yeyati PL, Idris AH, Hosono S, Haber DA, Licht JD, Atweh GF. The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene 1995;11:743–750.
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, Kishimoto T, Sugiyama H. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405–1412.
   PubMed Web of Science ®Google Scholar
• Sako M, Ogawa H, Okamura J, Tamaki H, Nakahata T, Kishimoto T, Sugiyama H. Abnormal expression of the Wilms’ tumor gene WT1 in juvenile chronic myeloid leukemia and infantile monosomy 7 syndrome. Leuk Res 1998;22:965–967.
   PubMed Web of Science ®Google Scholar
• Tamaki H, Ogawa H, Inoue K, Soma T, Yamagami T, Miyake S, Oka Y, Oji Y, Tatekawa T, Tsuboi A, Tagawa S, Kitani T, Aozasa K, Kishimoto T, Sugiyama H, Miwa H, Kita K. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood 1996;88:4396–4398.
   PubMed Web of Science ®Google Scholar
• Osaka M, Koami K, Sugiyama T. WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia. Int J Cancer 1997;72:696–699.
   PubMed Web of Science ®Google Scholar
• Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, Yao M, Takahashi E, Nakano Y, Hirabayashi H, Shintani Y, Oka Y, Tsuboi A, Hosen N, Asada M, Fujioka T, Murakami M, Kanato K, Motomura M, Kim EH, Kawakami M, Ikegame K, Ogawa H, Aozasa K, Kawase I, Sugiyama H. Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers. Int J Cancer 2002;100:297–303.
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, Oji Y, Tamaki H, Kyo T, Dohy H, Hiraoka A, Masaoka T, Kishimoto T, Sugiyama H. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996;88:2267–2278.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071–3079.
   PubMed Web of Science ®Google Scholar
• Saxena R, Sait S, Mhawech-Fauceglia P. Ewing sarcoma/primitive neuroectodermal tumor of the kidney: a case report. Diagnosed by immunohistochemistry and molecular analysis. Ann Diagn Pathol 2006;10:363–366.
   PubMedGoogle Scholar
• Sotobori T, Ueda T, Oji Y, Naka N, Araki N, Myoui A, Sugiyama H, Yoshikawa H. Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma. Cancer 2006;106:2233–2240.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Fuchs B, Zhang K, Ruan M, Halder C, Mahlum E, Weber K, Bolander ME, Sarkar G. High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res 2006;12:4237–4243.
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, Sugiyama H, Noguchi S. High expression of Wilms’ tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8:1167–1171.
   PubMed Web of Science ®Google Scholar
• Lung and pleural tumours. In UICC: TNM Classification of Malignant Tumours, 5th edition, L Sobin and C. Witterkind (eds). New York: John Wiley & Sons, 1997, 91–100.
   Google Scholar
• Hanson J, Gorman J, Reese J, Fraizer G. Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front Biosci 2007;12:2279–2290.
   PubMed Web of Science ®Google Scholar
• Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Haba R, Yokomise H. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 2001;92:2628–2638.
   PubMed Web of Science ®Google Scholar
• Tateishi U, Kusumoto M, Nishihara H, Nagashima K, Morikawa T, Moriyama N. Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer 2002;95:835–842.
   PubMed Web of Science ®Google Scholar
• Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC, Yang PC. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol 2002;20:900–910.
   PubMed Web of Science ®Google Scholar
• Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T, Yamazaki Y. Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 2001;92:1788–1797.
   PubMed Web of Science ®Google Scholar
• Fukata S, Inoue K, Kamada M, Kawada C, Furihata M, Ohtsuki Y, Shuin T. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer 2005;103:931–942.
   PubMed Web of Science ®Google Scholar
• Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997;79:206–213.
   PubMed Web of Science ®Google Scholar
• Dohi S, Ohno S, Ohno Y, Kyo S, Soma G, Sugiyama H, Inoue M. WT1 expression correlates with angiogenesis in endometrial cancer tissue. Anticancer Res 2010;30:3187–3192.
   PubMed Web of Science ®Google Scholar
• Moriya S, Takiguchi M, Seki N. Expression of the WT1 gene –KTS domain isoforms suppresses the invasive ability of human lung squamous cell carcinoma cells. Int J Oncol 2008;32:349–356.
   PubMed Web of Science ®Google Scholar
• Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T, Asada M, Jomgeow T, Aoyagi S, Nakano Y, Tamaki H, Sakaguchi N, Shirakata T, Nishida S, Kawakami M, Tsuboi A, Oka Y, Tsujimoto Y, Sugiyama H. Antiapoptotic function of 17AA(+)WT1 (Wilms’ tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 2006;25:4217–4229.
   PubMed Web of Science ®Google Scholar
• Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S, Fukuda I, Ito K, Nakamura J, Takashima S, Kitamura Y, Miyai S, Jomgeow T, Li Z, Shirakata T, Nishida S, Tsuboi A, Oka Y, Sugiyama H. Wilms’ tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol 2008;32:701–711.
   PubMed Web of Science ®Google Scholar
• Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, Nakazawa T, Tatsumi N, Sakaguchi N, Takashima S, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Itoh K, Sugiyama H. Wilms’ tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 2006;97:259–270.
   PubMed Web of Science ®Google Scholar
• Center for Cancer Control and Information Services, National Cancer Centre. Multiple Sites Survival. Bethesda, MD: National Cancer Institute, 2011.
   Google Scholar
• Chiba Y, Hashimoto N, Tsuboi A, Rabo C, Oka Y, Kinoshita M, Kagawa N, Oji Y, Sugiyama H, Yoshimine T. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumor Pathol 2010;27:29–34.
   PubMed Web of Science ®Google Scholar
• Lehe C, Ghebeh H, Al-Sulaiman A, Al Qudaihi G, Al-Hussein K, Almohareb F, Chaudhri N, Alsharif F, Al-Zahrani H, Tbakhi A, Aljurf M, Dermime S. The Wilms’ tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res 2008;68:6350–6359.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004;101:13885–13890.
   PubMed Web of Science ®Google Scholar
• Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, Inoue M, Mori M, Nakatsuka S, Sakaguchi N, Miyazaki K, Nakamura M, Fukuda I, Nakamura J, Tatsumi N, Takakuwa T, Nishida S, Shirakata T, Hosen N, Tsuboi A, Nezu R, Maeda H, Oka Y, Kawase I, Aozasa K, Okumura M, Miyoshi S, Sugiyama H. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer 2009;125:381–387.
   PubMed Web of Science ®Google Scholar
• Hewitt SM, Fraizer GC, Wu YJ, Rauscher FJ, 3rd, Saunders GF. Differential function of Wilms’ tumor gene WT1 splice isoforms in transcriptional regulation. J Biol Chem 1996;271: 8588–8592.
   PubMed Web of Science ®Google Scholar
• Burwell EA, McCarty GP, Simpson LA, Thompson KA, Loeb DM. Isoforms of Wilms’ tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Oncogene 2007;26:3423–3430.
   PubMed Web of Science ®Google Scholar